Advances in antibiotic therapy for acute pancreatitis.
10.3760/cma.j.issn.2095-4352.2018.07.019
- Author:
Xinyue HU
1
,
2
;
Lipeng ZHANG
Author Information
1. Department of Gastroenterology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010010, Inner Mongolia, China (Hu XY)
2. Department of Intensive Care Unit, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010010, Inner Mongolia, China (Zhang LP). Corresponding author: Zhang Lipeng, Email: zlp_boy2008@163.com.
- Publication Type:Journal Article
- MeSH:
Acute Disease;
Anti-Bacterial Agents;
Humans;
Multiple Organ Failure;
Pancreatitis;
Systemic Inflammatory Response Syndrome
- From:
Chinese Critical Care Medicine
2018;30(7):708-711
- CountryChina
- Language:Chinese
-
Abstract:
Severe acute pancreatitis (SAP) is still with a high incidence and mortality. Early onset is usually non-infectious inflammation caused by systemic inflammatory response syndrome (SIRS), with the further progress into pancreatic necrosis, which is the main cause of death. The occurrence of infection can induce or aggravate multiple organ failure (MOF), leading to death. Therefore, whether early use of antibiotics to prevent the occurrence of pancreatic infection and how to identify early pancreatic infection, how to choose the start of antibiotic therapy is the hot and difficult point of current study. Although multiple versions of the acute pancreatitis (AP) treatment guidelines don't recommend to prevent the use of antibiotics, its compliance in clinical practice is not high, which is explored in clinical research. This paper summarized the progress on research status of antibiotics for AP, to provide basis for the establishment of treatment of AP.
